Spirofurane derivatives
US5075317A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 21, 1989 |
| Grant date | Dec 24, 1991 |
| Priority date | — |
| Expiry date | Jun 21, 2009 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of general formula I, ##STR1## wherein R.sup.1 represents hydrogen or alkyl C.sub.1-3, PA1 R.sup.2 represents hydrogen or alkyl C.sub.1-6, PA1 n and m are integers from 1 to 3, provided that n+m=4, and PA1 one of X and Y represents CH.sub.2 and the other represents CHR.sup.3, C.dbd.O, C.dbd.CHR.sup.4 or C.dbd.NR.sup.5, in which PA1 R.sup.3, R.sup.4 and R.sup.5 are as defined in the specification, PA1 and their salts PA1 are useful as pharmaceuticals, in particular as central muscarinic acetylcholine receptors. The compounds are therefore useful in the treatment of diseases such as presenile and senile dementia, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania and Tourette Syndrome, and also as analgesic agents for use in the treatment of severe painful conditions such as rheumatism, arthritis, and terminal illness.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.